Roivant Sciences Ltd..
ROIV.US | Research and experimental development on natural sciences and engineering
Roivant Sciences Ltd. is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative therapies. It employs a hub-and-spoke model, creating subsidiary companies (Vants) focused on specific therapeutic areas or technologies. These Vants operate with significant autonom...Show More
Better Health for All
0
Insufficient evidence to determine a value score for Roivant Sciences Ltd. regarding Better Health for All. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary (75-100 words): Roivant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines. Their pipeline includes monoclonal antibodies and small molecule inhibitors targeting autoimmune and inflammatory diseases, as well as treatments for pulmonary hypertension. They also offer drug delivery platforms. Their focus is on developing novel therapies for diseases with unmet medical needs. The company is based in London and operates globally, conducting clinical trials and seeking regulatory approvals in various markets.
Peer Comparison (50-75 words): Compared to other biopharmaceutical companies, Roivant's focus on specific disease areas and novel drug delivery platforms is fairly standard. Many peers also target autoimmune and inflammatory diseases. The key differentiator may lie in the success of their clinical trials and the accessibility/pricing of their eventual products, which will determine their relative contribution to "Better Health for All."
Materiality Assessment (1-2 clear sentences): Roivant's business model is fundamentally supportive of the "Better Health for All" value, with a high level of materiality, as its core activities directly involve developing treatments for diseases and improving patient outcomes. The extent of this support depends on the accessibility and effectiveness of their therapies.
Detailed Rationale (150-200 words): Roivant's primary activity is developing and commercializing pharmaceutical products, directly impacting health outcomes. Their focus on diseases like rheumatoid arthritis, pulmonary hypertension, and other immune-mediated conditions addresses significant unmet medical needs. The company's success in clinical trials and subsequent market access will determine the extent of its positive impact. Factors such as pricing strategies, geographic availability, and patient assistance programs will influence the accessibility of their treatments, particularly for vulnerable populations. While the company's activities are inherently aligned with improving health, potential negative impacts could arise from adverse drug reactions or unethical marketing practices. Transparency in clinical trial data and responsible pricing are crucial for maximizing their positive contribution. The development of novel drug delivery platforms could also improve treatment efficacy and patient adherence, further supporting the value.
Value Interaction Notes (if applicable, 25-50 words): Roivant's pursuit of innovative therapies may involve complex patent strategies, potentially creating tension with the "Equitable Innovation" value if access to essential medicines is restricted in low-income countries.
Scoring Boundary Flags (if applicable, 25-50 words): A score below 4 would be illogical, as the company's core business directly addresses health needs. A score of 1 or 2 would only be justifiable if there were significant and systemic issues with drug safety, efficacy, or accessibility.
Fair Money & Economic Opportunity
0
No evidence available to assess Roivant Sciences Ltd. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
Roivant Sciences reported an employee survey satisfaction rate of 91%.
1
The company has no regulatory actions, violations, fines, or compliance issues mentioned across the provided articles.
2
No specific quantitative data was available for living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, turnover rate, insecure contract share, or health insurance coverage.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess Roivant Sciences Ltd. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete data points were found across the provided articles for any of the KPIs related to Honest & Fair Business. While some articles mention the existence of policies such as a whistleblower policy and an anti-corruption policy for Roivant Sciences, they do not provide sufficient detail or metrics (e.g., specific features, enforcement, coverage, or effectiveness) to map to any of the defined scoring tiers in the rubric.
1
Information regarding a whistleblower policy for the subsidiary Immunovant is not applicable to the parent company's overall score.
2
Similarly, there is no information on regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, or third-party verification of ethical claims for Roivant Sciences Ltd.
3
Kind to Animals
0
Roivant Sciences Ltd. conducts pre-clinical studies on animals to assess drug safety.
1
However, the provided articles do not offer specific data points regarding the company's animal testing policy, the volume of animals used, investment in animal-free alternatives, or any certifications related to cruelty-free practices or humane operations.
2
Therefore, no KPIs can be scored.
No War, No Weapons
0
No specific, concrete evidence was found in the provided articles to assess Roivant Sciences Ltd. against any of the 'No War, No Weapons' KPIs. The articles discuss general regulatory topics (e.g., SEC conflict minerals reporting rule
1
, EU export control for dual-use life sciences technologies
2
), other companies (e.g., Founders Fund
3
, Northrop Grumman
4
, Thomson Reuters
5
), or individuals, but do not link this information directly to Roivant Sciences Ltd.'s operations or performance.
Planet-Friendly Business
0
Roivant Sciences Ltd. has not publicly reported specific quantitative data for any of the planet-friendly business KPIs that meet the rubric's criteria for scoring. While the company has stated targets for greenhouse gas emissions reduction (50% by 2030), water consumption reduction (25% for research facilities), and waste management (40% for recyclable materials), these are forward-looking pledges and not evidence of achieved performance.
1
The company's annual emissions from research facilities, laboratory operations, and transportation total 2,660 metric tons of CO2, but there is no information on annual decline to match rubric thresholds.
2
The company reports an EPA Regulatory Compliance Score of 92/100 and an Environmental Audit Pass Rate of 98.5%, but these do not translate directly into the number of environmental compliance violations required by the rubric.
3
No other specific, concrete data points were found for any other KPIs.
Respect for Cultures & Communities
0
No evidence available to assess Roivant Sciences Ltd. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Roivant Sciences Ltd. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No quantitative data is available regarding Roivant Sciences's waste diversion rates, product recyclability, packaging sustainability, or other zero-waste metrics.
1
The company's corporate responsibility report mentions partnerships for electronics recycling and the use of water refill stations, but these initiatives lack specific, measurable outcomes or percentages to assess performance against the defined KPIs.
2
Therefore, no KPIs can be scored based on the provided evidence.